TW200504038A - 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors - Google Patents

3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors

Info

Publication number: TW200504038A
Authority: TW; Taiwan
Prior art keywords: propylcarbamoyl; benzothiazol; cycloalkyl; inhibitors; acid derivatives
Prior art date: 2003-03-14

Application number

TW093106666A

Other languages

English (en)

Chinese (zh)

Inventor

David Hepworth

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2004-03-12

Publication date

2005-02-01

2003-03-14 Priority claimed from GB0305916A external-priority patent/GB0305916D0/en

2003-12-16 Priority claimed from GB0329143A external-priority patent/GB0329143D0/en

2004-03-12 Application filed by Pfizer filed Critical Pfizer

2005-02-01 Publication of TW200504038A publication Critical patent/TW200504038A/zh

Links

239000003112 inhibitor Substances 0.000 title abstract 4
125000000753 cycloalkyl group Chemical group 0.000 title 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical class COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 title 1
206010057671 Female sexual dysfunction Diseases 0.000 abstract 4
208000021663 Female sexual arousal disease Diseases 0.000 abstract 2
102000003729 Neprilysin Human genes 0.000 abstract 2
108090000028 Neprilysin Proteins 0.000 abstract 2
206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)

TW093106666A 2003-03-14 2004-03-12 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors TW200504038A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0305916A GB0305916D0 (en)	2003-03-14	2003-03-14	New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en)	2003-12-16	2003-12-16	Novel pharmaceuticals

Publications (1)

Publication Number	Publication Date
TW200504038A true TW200504038A (en)	2005-02-01

Family

ID=32992599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW093106666A TW200504038A (en)	2003-03-14	2004-03-12	3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors

Country Status (25)

Country	Link
US (1)	US20040180941A1 (fr)
EP (1)	EP1606272A1 (fr)
JP (1)	JP3923512B2 (fr)
KR (1)	KR20050110003A (fr)
AP (1)	AP2005003393A0 (fr)
AR (1)	AR043551A1 (fr)
AU (1)	AU2004220269A1 (fr)
BR (1)	BRPI0408377A (fr)
CA (1)	CA2519072A1 (fr)
CL (1)	CL2004000512A1 (fr)
EA (1)	EA200501204A1 (fr)
EC (1)	ECSP056017A (fr)
HR (1)	HRP20050797A2 (fr)
IS (1)	IS8003A (fr)
MA (1)	MA27720A1 (fr)
MX (1)	MXPA05009788A (fr)
NL (1)	NL1025709C2 (fr)
NO (1)	NO20054169L (fr)
OA (1)	OA13039A (fr)
PA (1)	PA8597401A1 (fr)
PE (1)	PE20050310A1 (fr)
TN (1)	TNSN05227A1 (fr)
TW (1)	TW200504038A (fr)
UY (1)	UY28226A1 (fr)
WO (1)	WO2004080985A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007001348A (es) *	2004-08-02	2008-03-11	Bebaas Inc	Composiciones de vitamina b12.
WO2006027680A1 (fr) *	2004-09-10	2006-03-16	Pfizer Limited	Derives d'acide 3-(1-carbamoylcyclohexyl)propionique comme inhibiteurs de l'enzyme endopeptidase neutre
PT1830869E (pt)	2004-12-24	2013-08-22	Spinifex Pharm Pty Ltd	Método de tratamento ou profilaxia
AU2006275702A1 (en)	2005-07-29	2007-02-08	Concert Pharmaceuticals Inc.	Novel pharmaceutical compounds
US20070178141A1 (en) *	2005-09-07	2007-08-02	Bebaas, Inc.	Vitamin B12 compositions
US20130131007A1 (en)	2005-09-07	2013-05-23	Bebaas, Inc.	Vitamin b12 compositions
CA2646379C (fr) *	2006-03-20	2014-12-23	The University Of Queensland	Methode de traitement prophylactique ou therapeutique
WO2008021666A2 (fr) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Compositions stables de lévétiracétam et procédés
KR101177866B1 (ko)	2011-03-24	2012-08-28	주식회사 케이엠더블유	케이블 접속 장치
WO2019241585A1 (fr) *	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Méthodes de traitement d'une dysfonction érectile avec une composition pharmaceutique d'inhibiteur de phosphodiestérase 5 spécifique de cgmp
US20190385720A1 (en) *	2018-06-14	2019-12-19	AstraZeneca UK Litimited	Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
BR112021005532A2 (pt)	2018-09-25	2021-06-29	Antabio Sas	composto, composição farmacêutica e combinação
AU2020377914A1 (en) *	2019-11-08	2022-06-02	Vella Bioscience, Inc.	Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
GB202402524D0 (en) *	2024-02-22	2024-04-10	Futura Medical Developments Ltd	Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2503059A (en) *		1950-04-04		Nxchj
US2599000A (en) *	1950-09-02	1952-06-03	Smith Kline French Lab	Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) *	1963-10-17	1966-03-01	Sterling Drug Inc	1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) *	1965-12-15	1985-03-12	Acraf	Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) *	1967-12-13	1970-05-12	Pfizer & Co C	2,4,6,7-tetra substituted quinazolines
NL175059C (nl) *	1974-02-23		Boehringer Mannheim Gmbh	Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) *	1975-10-14	1977-05-31	Abbott Laboratories	Antihypertensive agents
US4188390A (en) *	1977-11-05	1980-02-12	Pfizer Inc.	Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) *	1978-02-06	1979-11-02	Synthelabo	Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) *	1978-04-18	1985-07-26	Acraf	Cicloalchiltriazoli
JPS56110665A (en) *	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) *	1985-08-05	1987-02-05	Hoechst Ag	Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CA2189355A1 (fr) *	1995-03-01	1996-09-06	Yasuo Onoda	Derives d'imidazoquinazoline
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2002079143A1 (fr) *	2001-03-28	2002-10-10	Pfizer Limited	Derives de guataramide n-phenpropylcyclopentyl-substitues utilises comme inhibiteurs nep pour fsad

2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Ceased
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-09 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 CA CA002519072A patent/CA2519072A1/fr not_active Abandoned
- 2004-03-09 EP EP04718706A patent/EP1606272A1/fr not_active Withdrawn
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/fr not_active Ceased
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown

Also Published As

Publication number	Publication date
HRP20050797A2 (en)	2006-02-28
JP2006526572A (ja)	2006-11-24
EP1606272A1 (fr)	2005-12-21
NO20054169L (no)	2005-12-07
PA8597401A1 (es)	2005-05-24
CL2004000512A1 (es)	2005-01-21
UY28226A1 (es)	2004-11-08
ECSP056017A (es)	2006-01-27
IS8003A (is)	2005-08-29
JP3923512B2 (ja)	2007-06-06
NL1025709A1 (nl)	2004-09-16
EA200501204A1 (ru)	2006-06-30
OA13039A (en)	2006-11-10
AU2004220269A1 (en)	2004-09-23
PE20050310A1 (es)	2005-05-04
US20040180941A1 (en)	2004-09-16
CA2519072A1 (fr)	2004-09-23
BRPI0408377A (pt)	2006-03-21
MXPA05009788A (es)	2005-10-26
MA27720A1 (fr)	2006-01-02
NL1025709C2 (nl)	2005-03-14
KR20050110003A (ko)	2005-11-22
AP2005003393A0 (en)	2005-09-30
NO20054169D0 (no)	2005-09-07
WO2004080985A1 (fr)	2004-09-23
TNSN05227A1 (fr)	2007-06-11
AR043551A1 (es)	2005-08-03

Publication	Publication Date	Title
TW200504038A (en)	2005-02-01	3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors
MXPA03011907A (es)	2004-03-26	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
WO2003002530A3 (fr)	2003-04-03	Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
GEP20084551B (en)	2008-11-25	4-phenylamino-quinazolin-6-yl-amides
MXPA05008172A (es)	2005-10-05	Derivados de malonamida como inhibidores gamma-secretasa.
SG151260A1 (en)	2009-04-30	5-substituted-2-phenylamino-benzamides as mek inhibitors
TW200505418A (en)	2005-02-16	Phenacyl 2-hydroxy-3-diaminoalkanes
MY162022A (en)	2017-05-31	Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
WO2005051914A8 (fr)	2005-08-11	Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
WO2008054698A3 (fr)	2008-06-19	Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
NO20025054D0 (no)	2002-10-21	Oksidasjonsprosess for fremstilling av mellomproduktet 6.alfa., 9.alfa.-difluor-11.beta., 17.alfa.-dihydroksy-16.alfa.-metyl-androst-1,4-dien-3-on 17.beta.-karboksylsyre
TW200726767A (en)	2007-07-16	Chemical compounds 2
UA83821C2 (ru)	2008-08-26	Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
MXPA04002282A (es)	2005-03-07	Nuevos compuestos y preparaciones como inhibidores de la catepsina.
IL158738A0 (en)	2004-05-12	Novel use of 2-phenyl-substituted imidazotriazinones
TW200407133A (en)	2004-05-16	Novel PPARα and PPARγ agonists
DE502005010342D1 (en)	2010-11-18	Substituierte cyclohexylessigsäure-derivate
WO2008036316A3 (fr)	2008-11-06	Inhibiteurs pipéridines et pyrrolidines de la bêta-secrétase utilisés dans le traitement de la maladie d'alzheimer
IL178167A0 (en)	2006-12-31	1,3,4-oxadiazol-2-ones as ppar delta modulators
TW200718688A (en)	2007-05-16	Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
WO2006041409A8 (fr)	2006-12-28	Solution medicale et son procede de production et d'utilisation
TW200745106A (en)	2007-12-16	Chemical compounds
TW200719889A (en)	2007-06-01	Amino acid derivatives
MXPA03001314A (es)	2004-04-05	Proceso para la preparacion de alfa'-clorocetonas.
HUP9801925A1 (hu)	2000-02-28	Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására